Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 29;22(13):6985.
doi: 10.3390/ijms22136985.

The Road to Low-Dose Aspirin Therapy for the Prevention of Preeclampsia Began with the Placenta

Scott W Walsh  1 , Jerome F Strauss 3rd  1
Affiliations
Review

The Road to Low-Dose Aspirin Therapy for the Prevention of Preeclampsia Began with the Placenta

Scott W Walsh et al. Int J Mol Sci. .

Abstract

The road to low-dose aspirin therapy for the prevention of preeclampsia began in the 1980s with the discovery that there was increased thromboxane and decreased prostacyclin production in placentas of preeclamptic women. At the time, low-dose aspirin therapy was being used to prevent recurrent myocardial infarction and other thrombotic events based on its ability to selectively inhibit thromboxane synthesis without affecting prostacyclin synthesis. With the discovery that thromboxane was increased in preeclamptic women, it was reasonable to evaluate whether low-dose aspirin would be effective for preeclampsia prevention. The first clinical trials were very promising, but then two large multi-center trials dampened enthusiasm until meta-analysis studies showed aspirin was effective, but with caveats. Low-dose aspirin was most effective when started <16 weeks of gestation and at doses >100 mg/day. It was effective in reducing preterm preeclampsia, but not term preeclampsia, and patient compliance and patient weight were important variables. Despite the effectiveness of low-dose aspirin therapy in correcting the placental imbalance between thromboxane and prostacyclin and reducing oxidative stress, some aspirin-treated women still develop preeclampsia. Alterations in placental sphingolipids and hydroxyeicosatetraenoic acids not affected by aspirin, but with biologic actions that could cause preeclampsia, may explain treatment failures. Consideration should be given to aspirin's effect on neutrophils and pregnancy-specific expression of protease-activated receptor 1, as well as additional mechanisms of action to prevent preeclampsia.

Keywords: eicosanoids; isoprostanes; low-dose aspirin; neutrophils; placenta; preeclampsia; prostacyclin; protease-activated receptor 1; sphingolipids; thromboxane.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Production of prostacyclin and thromboxane in normal and preeclamptic placentas.
Figure 2
Figure 2
Significant reduction in preeclampsia.
Figure 3
Figure 3
Modest reduction in preeclampsia.
Figure 4
Figure 4
Importance of compliance for low-dose aspirin therapy.
Figure 5
Figure 5
Placental production of cyclooxygenase metabolites and isoprostanes in women with severe preeclampsia receiving low-dose aspirin, * p < 0.05.
Figure 6
Figure 6
Mechanism for selective inhibition of placental thromboxane (TX) by low-dose aspirin (ASA). Prostacyclin (PGI2).
Figure 7
Figure 7
Mechanism for inhibition of isoprostanes by aspirin (ASA).
Figure 8
Figure 8
Increases in HETEs related to the development of preeclampsia, ** p < 0.01, *** p < 0.001.
Figure 9
Figure 9
Interconversion of sphingolipids. (DAG, diacylglycerol; PKC, protein kinase C).
Figure 10
Figure 10
Increases in sphingolipids related to the development of preeclampsia, * p < 0.05, ** p < 0.01.
Figure 11
Figure 11
Neutrophils (brown) in omental fat arteries.
Figure 12
Figure 12
Expression of PAR-1 in omental vessels.
Figure 13
Figure 13
Confocal images of TET2 and p65 immuno-fluorescence staining in neutrophils of normal pregnant women. Nuclear localization induced by protease treatment was prevented by inhibition of PAR-1. Images were taken with a Zeiss LSM 700 using x63 lens and then cropped.
Figure 14
Figure 14
TET2 in omental vessels (A–D).
Figure 15
Figure 15
Molecular mechanism for protease activation of pregnancy neutrophils.
Figure 16
Figure 16
Expression of PAR-1 in syncytiotrophoblasts and macrophages in the placenta (dark brown staining).
Figure 17
Figure 17
Clinical manifestations of preeclampsia that can be explained by protease activation of PAR-1.
See this image and copyright information in PMC

References

    1. Moncada S., Gryglewski R.J., Bunting S., Vane J.R. A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins. 1976;12:715–737. doi: 10.1016/0090-6980(76)90048-4. - DOI - PubMed
    1. Moncada S., Vane J.R. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol. Rev. 1979;30:293–331. - PubMed
    1. Bunting S., Moncada S., Vane J.R. The prostacyclin--thromboxane A2 balance: Pathophysiological and therapeutic implications. Br. Med. Bull. 1983;39:271–276. doi: 10.1093/oxfordjournals.bmb.a071832. - DOI - PubMed
    1. Lewis H.D., Jr., Davis J.W., Archibald D.G., Steinke W.E., Smitherman T.C., Doherty J.E., 3rd, Schnaper H.W., LeWinter M.M., Linares E., Pouget J.M., et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med. 1983;309:396–403. doi: 10.1056/NEJM198308183090703. - DOI - PubMed
    1. Marcus A.J. Aspirin as an Antithrombotic Medication. N. Engl. J. Med. 1983;309:1515–1517. doi: 10.1056/NEJM198312153092410. - DOI - PubMed

MeSH terms

LinkOut - more resources